Vivos Reports Q1 Revenue of $5.14M, Exceeding Expectations
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 20 2026
0mins
Reports Q1 revenue $5.14M, consensus $4.35M. Kirk Huntsman, Vivos' chairman and CEO, stated "Our significant revenue increase year over year and quarter over quarter confirms what we emphatically stated when we reported our 2025 year end results last month: that the fourth quarter of 2025 was not fully indicative of our overall growth trajectory, which remains strong and is accelerating here in the second quarter. Our June 2025 acquisition of SCN and business model pivot continues to drive patient volume and top-line revenue, and we are working hard to increase the daily productivity of SCN doctors and insurance reimbursement. Importantly, and as expected, we are seeing a very significant reduction in customer acquisition costs. So, our goal is continued integration of, and growth from, SCN and other medical provider collaborations, and our current results demonstrate that this is achievable going forward. Meanwhile, we have implemented significant cost savings measures, and have simultaneously been working to secure new funding to meet our operating needs and to restructure our debt in order to improve our stockholders' equity and reduce cash burn, all with the goal of getting us to cash flow positive operations as soon as possible."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy VVOS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on VVOS
Wall Street analysts forecast VVOS stock price to rise
3 Analyst Rating
2 Buy
1 Hold
0 Sell
Moderate Buy
Current: 0.511
Low
2.50
Averages
5.00
High
7.00
Current: 0.511
Low
2.50
Averages
5.00
High
7.00
About VVOS
Vivos Therapeutics, Inc. is a medical technology company focused on developing and commercializing diagnostic and treatment methods that promote sleep wellness and health for patients suffering from breathing and sleep issues such as obstructive sleep apnea (OSA) and snoring in adults. The Company's Complete Airway Repositioning and/or Expansion (CARE) devices are the oral appliances cleared by the United States Food and Drug Administration (FDA) for adult patients diagnosed with all severity levels of OSA (including severe OSA) and moderate-to-severe OSA in children ages 6 to 17 within the FDA cleared usage for such devices. The Company's products and services include Vivos CARE oral appliance therapy, Vivos oral appliances and therapies outside of CARE system, Vivos AireO2, Adjunctive Treatment, Treatment Navigator, Vivos Billing Intelligence Service (BIS) and Vivos Airway Intelligence Service, and others. The Company has sleep testing centers and associated medical sleep practice.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Vivos Therapeutics Plans Rights Offering to Raise Capital
- Rights Offering Announcement: Vivos Therapeutics has announced its intention to file a registration statement with the SEC for a proposed rights offering, which will distribute transferable subscription rights as a dividend to shareholders, aimed at raising additional capital to support operations.
- Subscription Rights Terms: Each right is expected to allow the purchase of one share of Vivos common stock at an exercise price of $1.25 or 20% above the market price on the day before the record date, with the final price detailed in the prospectus and a nine-month exercise period.
- Subsequent Rights Provision: Upon exercising a right, holders will receive a similar nine-month trading right with an expected exercise price of $1.75 or 40% above the market price prior to the record date, enhancing potential returns for investors.
- Conditions and Uncertainties: The rights offering is subject to several conditions, including SEC effectiveness, compliance with regulatory requirements, and board approvals, with any unmet conditions potentially delaying or preventing the offering, thus increasing uncertainty for investors.
See More
Vivos Collaborates with South Palm Cardiovascular to Enhance Sleep Disorder Treatment
- Collaboration Agreement: Vivos Therapeutics has entered into a collaboration agreement with South Palm Cardiovascular Associates to establish AIM Florida, aimed at expanding integrated diagnostic and therapeutic services for cardiovascular disease patients, which is expected to significantly enhance treatment outcomes and quality of life for patients.
- Significant Market Potential: AIM Florida plans to initially serve approximately 250 patients, generating over $6 million annually with contribution margins approaching 50%, which will provide robust support for Vivos' cash flow and profitability.
- Innovative Medical Collaboration Model: This partnership directly engages the medical community, avoiding the substantial capital outlays associated with traditional acquisitions, showcasing a scalable and compliant business model that is expected to attract more similar medical collaborations.
- Addressing Medical Shortages: The collaboration aims to tackle the challenges faced by cardiovascular patients in accessing treatment for sleep disorders, particularly against the backdrop of a shortage of certified sleep medicine specialists, enhancing diagnostic and treatment efficiency through the partnership with SPCVA.
See More
Vivos Therapeutics to Participate in Small Cap Showcase
- Executive Presentation: Vivos Therapeutics' CEO Kirk Hunstman will deliver a corporate presentation at the Small Cap Showcase & WTR Insights on June 9, 2026, in New York City, aiming to attract investor interest in its innovative treatments for breathing-related sleep disorders.
- Market Opportunity Exploration: The event gathers management teams from approximately 20 micro and small-cap companies, providing a unique platform for investors to discover differentiated investment opportunities through company presentations, industry insights, and networking, thereby enhancing Vivos' visibility in the capital markets.
- Innovative Technology Promotion: Vivos' Complete Airway Repositioning and Expansion (CARE) devices are the only FDA 510(k) cleared technology for treating severe obstructive sleep apnea in adults, which is expected to draw increased attention and drive sales growth, especially given that over 1 billion people globally are affected by this condition.
- Future Development Strategy: By participating in this showcase, Vivos reinforces its leadership in the respiratory health sector, aiming to enhance healthcare providers' capabilities in treating OSA patients through innovative technology and education, thereby positioning itself favorably in a competitive market.
See More
Vivos Therapeutics Q1 Earnings Exceed Expectations
- Earnings Report: Vivos Therapeutics reported a Q1 GAAP EPS of -$0.52, missing expectations by $0.07, indicating ongoing challenges in achieving profitability.
- Revenue Growth: The company achieved Q1 revenue of $5.14 million, representing a 70.2% year-over-year increase and exceeding market expectations by $0.79 million, suggesting sustained demand for its products that could enhance future market share.
- Cash Flow Status: As of March 31, 2026, Vivos had cash and cash equivalents of $2.1 million, with stockholders' equity reflecting a deficit of $1.1 million, highlighting financial health concerns.
- Future Outlook: Vivos aims to achieve cash flow positive operations by the end of 2026, targeting over $500,000 in monthly collections, which, if realized, would significantly improve the company's financial condition and bolster investor confidence.
See More
Vivos Therapeutics Reports 16% Revenue Growth in 2025
- Revenue Growth: Vivos Therapeutics reported a $2.4 million increase in full-year 2025 revenue, a 16% rise primarily driven by the acquisition of the Sleep Center of Nevada (SCN) and increased sleep testing services, enhancing its market competitiveness.
- Gross Profit Increase: The company achieved a gross profit of $10.5 million in 2025, a 17% increase from 2024, maintaining a consistent gross margin of 60%, indicating effective cost control and business integration.
- Rising Operating Expenses: Operating expenses surged to $30.4 million in 2025 from $20.2 million in 2024, primarily due to increased general and administrative costs associated with the new business model, reflecting financial pressure during the transition.
- Widening Net Loss: Vivos Therapeutics reported a net loss of $21.2 million for 2025, reflecting high costs associated with strategic transitions, while facing provider shortages that led to revenue declines, impacting overall financial health.
See More
Vivos Therapeutics Reports Increased Annual Loss
- Increased Annual Loss: Vivos Therapeutics reported a full-year loss of $21.17 million, translating to a loss of $2.07 per share, which is a deterioration compared to last year's loss of $11.14 million and $2.22 per share, indicating worsening financial health.
- Revenue Growth: Despite the increased losses, the company's revenue rose by 16% to $17.44 million from $15.03 million last year, suggesting that Vivos still possesses some sales capability in the market.
- Earnings Per Share Comparison: The loss per share improved slightly from $2.22 last year to $2.07, indicating a reduction in losses; however, it still reflects ongoing challenges faced by the company in reversing its overall financial performance.
- Market Reaction: Given the persistent losses and financial pressures, investors may adopt a cautious stance regarding the company's future prospects, potentially impacting its stock price performance and market confidence.
See More
Vivos Therapeutics Plans Rights Offering to Raise Capital
- Rights Offering Announcement: Vivos Therapeutics has announced its intention to file a registration statement with the SEC for a proposed rights offering, which will distribute transferable subscription rights as a dividend to shareholders, aimed at raising additional capital to support operations.
- Subscription Rights Terms: Each right is expected to allow the purchase of one share of Vivos common stock at an exercise price of $1.25 or 20% above the market price on the day before the record date, with the final price detailed in the prospectus and a nine-month exercise period.
- Subsequent Rights Provision: Upon exercising a right, holders will receive a similar nine-month trading right with an expected exercise price of $1.75 or 40% above the market price prior to the record date, enhancing potential returns for investors.
- Conditions and Uncertainties: The rights offering is subject to several conditions, including SEC effectiveness, compliance with regulatory requirements, and board approvals, with any unmet conditions potentially delaying or preventing the offering, thus increasing uncertainty for investors.
See More
Vivos Collaborates with South Palm Cardiovascular to Enhance Sleep Disorder Treatment
- Collaboration Agreement: Vivos Therapeutics has entered into a collaboration agreement with South Palm Cardiovascular Associates to establish AIM Florida, aimed at expanding integrated diagnostic and therapeutic services for cardiovascular disease patients, which is expected to significantly enhance treatment outcomes and quality of life for patients.
- Significant Market Potential: AIM Florida plans to initially serve approximately 250 patients, generating over $6 million annually with contribution margins approaching 50%, which will provide robust support for Vivos' cash flow and profitability.
- Innovative Medical Collaboration Model: This partnership directly engages the medical community, avoiding the substantial capital outlays associated with traditional acquisitions, showcasing a scalable and compliant business model that is expected to attract more similar medical collaborations.
- Addressing Medical Shortages: The collaboration aims to tackle the challenges faced by cardiovascular patients in accessing treatment for sleep disorders, particularly against the backdrop of a shortage of certified sleep medicine specialists, enhancing diagnostic and treatment efficiency through the partnership with SPCVA.
See More
Vivos Therapeutics to Participate in Small Cap Showcase
- Executive Presentation: Vivos Therapeutics' CEO Kirk Hunstman will deliver a corporate presentation at the Small Cap Showcase & WTR Insights on June 9, 2026, in New York City, aiming to attract investor interest in its innovative treatments for breathing-related sleep disorders.
- Market Opportunity Exploration: The event gathers management teams from approximately 20 micro and small-cap companies, providing a unique platform for investors to discover differentiated investment opportunities through company presentations, industry insights, and networking, thereby enhancing Vivos' visibility in the capital markets.
- Innovative Technology Promotion: Vivos' Complete Airway Repositioning and Expansion (CARE) devices are the only FDA 510(k) cleared technology for treating severe obstructive sleep apnea in adults, which is expected to draw increased attention and drive sales growth, especially given that over 1 billion people globally are affected by this condition.
- Future Development Strategy: By participating in this showcase, Vivos reinforces its leadership in the respiratory health sector, aiming to enhance healthcare providers' capabilities in treating OSA patients through innovative technology and education, thereby positioning itself favorably in a competitive market.
See More
Vivos Therapeutics Q1 Earnings Exceed Expectations
- Earnings Report: Vivos Therapeutics reported a Q1 GAAP EPS of -$0.52, missing expectations by $0.07, indicating ongoing challenges in achieving profitability.
- Revenue Growth: The company achieved Q1 revenue of $5.14 million, representing a 70.2% year-over-year increase and exceeding market expectations by $0.79 million, suggesting sustained demand for its products that could enhance future market share.
- Cash Flow Status: As of March 31, 2026, Vivos had cash and cash equivalents of $2.1 million, with stockholders' equity reflecting a deficit of $1.1 million, highlighting financial health concerns.
- Future Outlook: Vivos aims to achieve cash flow positive operations by the end of 2026, targeting over $500,000 in monthly collections, which, if realized, would significantly improve the company's financial condition and bolster investor confidence.
See More
Vivos Therapeutics Reports 16% Revenue Growth in 2025
- Revenue Growth: Vivos Therapeutics reported a $2.4 million increase in full-year 2025 revenue, a 16% rise primarily driven by the acquisition of the Sleep Center of Nevada (SCN) and increased sleep testing services, enhancing its market competitiveness.
- Gross Profit Increase: The company achieved a gross profit of $10.5 million in 2025, a 17% increase from 2024, maintaining a consistent gross margin of 60%, indicating effective cost control and business integration.
- Rising Operating Expenses: Operating expenses surged to $30.4 million in 2025 from $20.2 million in 2024, primarily due to increased general and administrative costs associated with the new business model, reflecting financial pressure during the transition.
- Widening Net Loss: Vivos Therapeutics reported a net loss of $21.2 million for 2025, reflecting high costs associated with strategic transitions, while facing provider shortages that led to revenue declines, impacting overall financial health.
See More
Vivos Therapeutics Reports Increased Annual Loss
- Increased Annual Loss: Vivos Therapeutics reported a full-year loss of $21.17 million, translating to a loss of $2.07 per share, which is a deterioration compared to last year's loss of $11.14 million and $2.22 per share, indicating worsening financial health.
- Revenue Growth: Despite the increased losses, the company's revenue rose by 16% to $17.44 million from $15.03 million last year, suggesting that Vivos still possesses some sales capability in the market.
- Earnings Per Share Comparison: The loss per share improved slightly from $2.22 last year to $2.07, indicating a reduction in losses; however, it still reflects ongoing challenges faced by the company in reversing its overall financial performance.
- Market Reaction: Given the persistent losses and financial pressures, investors may adopt a cautious stance regarding the company's future prospects, potentially impacting its stock price performance and market confidence.
See More
